Scroll to top

Managing Director’s AGM Presentation

27 November 2016

Good morning and welcome to CLINUVEL’s Annual General Meeting. The challenges ahead for 2017 are to reconcile the asymmetry in knowledge with regulators, governmental advisory bodies, payors, medical community and press on CLINUVEL’s innovative technology SCENESSE® (afamelanotide 16mg)1 and to differentiate CLINUVEL from other companies in our sector.

Download PDF for more

We use cookies to give you the best experience.